Overview of Immunotherapy

Laura J. Zitella, R. Donald Harvey and Mollie Reed

Posted: 12/1/2017
Expires: 5/31/2018
Credits/Contact Hours: 2.25

Instructions for Earning CE credit

If you would like to earn credit, you must take the pre-test first by clicking here

Begin Pre-test


Related Material

Is programmed cell death ligand 1 (PD-L1) testing necessary?
When should you image patients to assess response to immunotherapy?
Why is pseudo-progression an important issue in patients on immune checkpoint inhibitors?
What are the mechanisms of action and adverse effects of these agents?
How do responses to immune checkpoint inhibitors differ from responses to chemotherapy?
What cancers are most likely to respond to immunotherapy?
How do you educate patients about the timing of early and latent side effects?
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here